HomeCompareBCEL vs ORCC

BCEL vs ORCC: Dividend Comparison 2026

BCEL yields 2222.22% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BCEL wins by $26607504688.24M in total portfolio value
10 years
BCEL
BCEL
● Live price
2222.22%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26607504688.26M
Annual income
$24,443,703,761,807,280.00
Full BCEL calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — BCEL vs ORCC

📍 BCEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBCELORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BCEL + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BCEL pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCEL
Annual income on $10K today (after 15% tax)
$188,888.89/yr
After 10yr DRIP, annual income (after tax)
$20,777,148,197,536,188.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, BCEL beats the other by $20,777,148,197,536,188.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCEL + ORCC for your $10,000?

BCEL: 50%ORCC: 50%
100% ORCC50/50100% BCEL
Portfolio after 10yr
$13303752344.14M
Annual income
$12,221,851,880,903,640.00/yr
Blended yield
91.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

BCEL
Analyst Ratings
4
Buy
4
Hold
Consensus: Buy
Price Target
$4.00
+4344.4% upside vs current
Range: $4.00 — $4.00
Altman Z
-37.6
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCEL buys
0
ORCC buys
0
No recent congressional trades found for BCEL or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBCELORCC
Forward yield2222.22%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$26607504688.26M$21.4K
Annual income after 10y$24,443,703,761,807,280.00$1.04
Total dividends collected$26455115546.17M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$4.00$16.00

Year-by-year: BCEL vs ORCC ($10,000, DRIP)

YearBCEL PortfolioBCEL Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$232,922$222,222.22$11,190$489.61+$221.7KBCEL
2$5,086,656$4,837,429.33$12,229$256.01+$5.07MBCEL
3$104,173,443$98,730,720.93$13,216$130.74+$104.16MBCEL
4$2,001,166,924$1,889,701,340.37$14,207$66.02+$2001.15MBCEL
5$36,067,485,611$33,926,237,001.88$15,234$33.17+$36067.47MBCEL
6$610,050,404,477$571,458,194,873.63$16,317$16.62+$610050.39MBCEL
7$9,686,139,336,337$9,033,385,403,546.24$17,468$8.32+$9686139.32MBCEL
8$144,409,519,569,037$134,045,350,479,156.38$18,695$4.16+$144409519.55MBCEL
9$2,022,243,856,495,371$1,867,725,670,556,501.50$20,006$2.08+$2022243856.48MBCEL
10$26,607,504,688,257,330$24,443,703,761,807,280.00$21,407$1.04+$26607504688.24MBCEL

BCEL vs ORCC: Complete Analysis 2026

BCELStock

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Full BCEL Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this BCEL vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCEL vs SCHDBCEL vs JEPIBCEL vs OBCEL vs KOBCEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.